FMS Fresenius Medical Care AG

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 of the

Securities Exchange Act of 1934

For the month of July 2016

FRESENIUS MEDICAL CARE AG & Co. KGaA

(Translation of registrant’s name into English)

Else-Kröner Strasse 1

61346 Bad Homburg

Germany

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82

On June 30, 2016, Dr. Ulf Schneider resigned from his position as Chief Executive Officer of Fresenius SE & Co. KGaA (“Fresenius SE”), Chairman of the Management Board of Fresenius Management SE “Management SE”) and Chairman of the Supervisory Board of Fresenius Medical Care Management AG (“Management AG”) as well as his various other board positions within the Fresenius SE group.  On June 30, 2016, Mr. Stephan Sturm assumed the roles of Chief Executive Officer of Fresenius SE, Chairman of the Board of Management SE and Chairman of the Supervisory Board of Management AG.

2